1 Start 2 Complete

After attending this session I can now demonstrate the identified learning objectives *

	Yes	No
Apply the latest data on biologics in asthma and nasal polyps to the patient population with AERD	Apply the latest data on biologics in asthma and nasal polyps to the patient population with AERD - Yes	Apply the latest data on biologics in asthma and nasal polyps to the patient population with AERD - No
Identify patients with AERD who should be considered for aspirin desensitization	Identify patients with AERD who should be considered for aspirin desensitization - Yes	Identify patients with AERD who should be considered for aspirin desensitization - No
Define the benefits and risks of aspirin and biologic therapy for patients with AERD	Define the benefits and risks of aspirin and biologic therapy for patients with AERD - Yes	Define the benefits and risks of aspirin and biologic therapy for patients with AERD - No

The session format and teaching technique were appropriate for the content. *

Yes

No

This session met my expectations based on the session description and learning objectives. *

Yes

No

I observed objective, balanced content that demonstrated no bias in favor of goods or services of a commercial interest. *

Yes

No

Speaker/Moderator was engaging and provided accurate, valuable content *

	Yes	No
Elina Jerschow, MD FAAAAI	Elina Jerschow, MD FAAAAI - Yes	Elina Jerschow, MD FAAAAI - No
Whitney Stevens, MD	Whitney Stevens, MD - Yes	Whitney Stevens, MD - No
Katherine N. Cahill, MD	Katherine N. Cahill, MD - Yes	Katherine N. Cahill, MD - No
Tanya M. Laidlaw, MD FAAAAI	Tanya M. Laidlaw, MD FAAAAI - Yes	Tanya M. Laidlaw, MD FAAAAI - No

If you responded no to any questions, or have other comments about this session, please explain.

Please provide any additional feedback about the faculty in this session:

Leave this field blank